Research Article: Tocilizumab Vs Methotrexate in a Cohort of Patients Affected by Active GCA: A Comparative Clinical and Ultrasonographic Study
Introduction:
The approval of Tocilizumab (TCZ) has dramatically changed the therapeutic approach and prognosis of giant cell arteritis (GCA). Glucocorticoids (GCs), burdened by poor long-term efficacy, a high rate of relapse, and several side effects, appear to be surpassed by a molecule that has proven its superiority in a Phase III trial and in some real-life studies.
Read more